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Orthopoxvirus zoonosis or smallpox as result of bioter-
rorism or biological warfare represents a risk for epidemic
spread. By monitoring T-cell responses by flow cytometry,
we observed a recall response after recent vaccination
against smallpox. When the high similarity between the
orthopoxviruses is considered, this rapid assay that uses
vaccinia antigens could identify recently exposures.
A
lthough the last natural case of smallpox was report-
ed in Somalia in 1977, this orthopoxvirus remains a
source of concern. No evidence exists that smallpox will
recur as an endemic disease, but the virus may have been
acquired for use in biological warfare or bioterrorist
attacks. If one assumes an average of 15 days is needed
for infected persons to become infectious, delay in inter-
vention will be costly, increasing the total number of cases
(1). Furthermore, the recent outbreak of the severe acute
respiratory syndrome coronavirus and the first document-
ed outbreak of monkeypoxvirus in the Western
Hemisphere underline the ever-present risk for epidemic
extension of zoonosis and raise concerns about the med-
ical and social effect of reemerging orthopoxvirus infec-
tion in humans. During the epidemic spread of an emerg-
ing pathogen, evaluating exposed persons and containing
the infected population should be the first priorities. A
local outbreak of orthopoxvirus infection would require
rapid and sensitive diagnostics, including novel assays
based on host responses.
For intracellular pathogens, the antibody titers and neu-
tralization assays represent routine immunologic tests that
provide results after several weeks of infection. The
appearance of a detectable antibody titer takes place a few
days after the induction of a T-cell response (2). Moreover,
antigen-specific T-cell responses could be detected in
exposed, but uninfected persons, as shown in those with
HIV infection (3). Using a rapid flow cytometric test, we
previously showed that monitoring interferon (IFN)-γ pro-
duction by antigen-pulsed T cells provides a quantitative
and functional assessment of HIV- or cytomegalovirus
(CMV)-specific CD8(+) and CD4(+) T cells (4–6). This
technique requires that whole proteins or selected peptide
antigens are added to blood cells, allowing the simultane-
ous analysis of both major histocompatibility complex
class I and II restricted T-cell responses (7). Because
smallpox vaccination was recently shown to induce a
strong vaccinia virus-specific CD8(+) CTL- and IFN-
γ–producing T cells detectable by more cumbersome
research laboratory methods (cytotoxic, proliferative, or
ELISPOT assays) (8,9), we evaluated the feasibility of an
easy, rapid, and sensitive assay to monitor T-cell respons-
es after recent vaccination against smallpox; the assay can
potentially be used as a routine diagnostic assay.
The Study
T-cell reactivity was analyzed after recent (<2 years
ago) smallpox vaccinations, in long-term vaccinated (>20
years ago) and not vaccinated persons. Briefly, peripheral
blood mononuclear cells (PBMC) were isolated by stan-
dard density centrifugation (Ficoll-Hypaque, Pharmacia,
Uppsala, Sweden). Stimulation was also performed on
whole blood samples; however, the assay had reduced sen-
sitivity. We cannot exclude the possibility that whole blood
assay sensitivity could be improved by changing protocol
conditions (data not shown). PBMC were cultured in com-
plete Roswell Park Memorial Institute 1640 medium, 10%
v/v heat-inactivated fetal calf serum, 2 mM L-glutamine,
and 10 U/mL penicillin/streptomycin at a concentration of
106 cells/mL. Stimulation was performed with 40 µL/mL
(total protein content of approximately 1 µg/mL) of vac-
cinia viral antigen resuspended according to the manufac-
turer’s instructions (Maine Biotechnology Services,
Portland, ME), or 2 µg of CMV antigen (Biowhittaker,
Walkersville, MD), always in the presence of co-stimula-
tion with both anti-CD28 and CD49d monoclonal antibod-
ies (1 µg/mL, Becton, Dickinson and Company, Franklin
Lakes, NJ). We also tested the T-cell response with live
vaccinia-infected fibroblast or Vero cells. The response
against uninfected antigenic preparations was always
above background, reducing the sensitivity of the assay
(data not shown); therefore, the commercially available
antigens were used in subsequent experiments. Cultures
were incubated at 37°C for 1 h, followed by an additional
overnight incubation with 10 µg/mL of the secretion
inhibitor Brefeldin-A (Sigma-Aldrich Corporation, St.
Louis, MO). Cells were washed twice in phosphate-
buffered saline, 1% bovine serum albumin, and 0.1% sodi-
um azide, and stained for 15 min at 4°C with monoclonal
antibodies specific for cell surface CD antigens (Becton,
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paraformaldehyde for 10 min at 4°C, incubated with
Phyco-Erithrin-conjugated mouse-anti-human IFN-γ
(Becton, Dickinson and Company), washed twice in phos-
phate-buffered saline, 1% bovine serum albumin, and
0.1% saponin, and resuspended in FACSFlow before being
acquired on FACScalibur (Becton, Dickinson and
Company), as previously described (4,6). Controls for
nonspecific staining were monitored with isotype-matched
monoclonal antibodies (Becton, Dickinson and Company);
cells incubated with only anti-CD28 and -CD49d were
included in each experiment and nonspecific staining was
always subtracted from specific results. In the cytometric
panels shown in the Figure, the IFN-γ production by CD3
(-) cells is 1 log lower in intensity compared to the antigen-
specific CD3(+) T-cell response, representing an unspecif-
ic response that may involve natural killer cells. To moni-
tor antigen-specific T-cell responses, we collected data
only from CD3(+) T cells producing higher amounts of
IFN-γ. Negative control antigenic stimulation was always
below the detection limit of the assay (0.02%). 
Cytometric panels in the Figure show the IFN-γ synthe-
sis by CD3(+) T cells after in vitro stimulation with vac-
cinia virus or CMV antigens. As shown in panels D, E, and
F, all donors were strongly reactive to the CMV antigens
(0.87%, 0.20%, and 1.53% of CD3(+) T cells respectively;
the numbers of CMV-specific CD3(+) T cells per blood
milliliter were 13,132, 2,964, and 11,385, respectively). As
previously described (6), most of the CMV-specific
response was related to CD4(+) T cells (96%, 75%, and
59% of CMV-specific T cells, respectively). Both unvacci-
nated and long-term vaccinated healthy donors had unde-
tectable responses to smallpox vaccinia antigens (Figure,
panels A and B). In contrast, a recall response was
detectable after a recent immunization (Figure, panel C).
In this case, the percentage of T cells specific for smallpox
vaccine antigens was 0.23% among CD3(+) T cell , and
the number of vaccinia antigen-specific cells was 1,725
per blood mL corresponding to a frequency of 1/667. Most
vaccinia-specific T cells detected by this assay were
CD4(+) (vaccinia-specific CD4(+) T cells were 80% of
vaccinia-specific T cells). Nevertheless, the sensitivity of
this assay to detect CD8(+) T cells could be improved by
using human leukocyte antigen (HLA) class I–specific
peptides as previously described (4). 
Conclusions
Vigorous and long-lasting protective immune responses
have been associated with smallpox vaccination, and spe-
cific immunity is believed to be maintained for decades
(10,11). In long-term vaccinated persons, virus-specific
CD4(+) and CD8(+) T-lymphocytes are detectable only
after extensive in vitro culture and restimulation to generate
antigen-specific lines or clones. This limitation is due to the
long, but limited, lifespan of memory T cells and to their
low frequency, usually below 1/50,000 (12). Our in vitro
rapid assay based on a short-time primary T-cell response
was unable to show the residual memory T-cell response
present in long-term vaccinated persons since the assay
sensitivity is 1 log lower but could detect the higher fre-
quencies of IFN-γ–producing antigen-specific cells appear-
ing a few weeks after smallpox vaccine inoculation (8).
Accordingly, Terajima et al. (13) demonstrated that T-cell
responses to vaccinia and variola conserved epitopes peak
14 days after primary immunization with vaccinia virus. In
this study, the frequency of antigen-specific T cells was
measured as IFN-γ production by ELISPOT and HLA/pep-
tide tetramer–staining methods. Because strong correla-
tions between the data derived from ELISPOT, tetramer
assays, and intracellular cytokine staining for IFN-γ were
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Figure. Flow cytometric analysis of T-cell responses to smallpox
antigens after recent smallpox vaccination and in long-term vacci-
nated or not vaccinated persons. Interferon (IFN)-γ synthesis by T
cells after an in vitro stimulation with vaccinia antigens was ana-
lyzed in eight healthy donors selected as recently vaccinated, long-
term vaccinated, and not vaccinated persons. A representative
experiment is reported in this figure. Panels A and D refer to an
unvaccinated healthy donor (25-year-old white man, current neu-
tralizing antibodies absent). A long-term vaccinated healthy person
is reported in panels B and E (29-year-old white man received two
doses of vaccine virus by scarification >20 years ago, current vac-
cinia neutralizing antibody titer of 1:8). Results from a recently vac-
cinated person are shown in panels C and F (31-year-old white
man, single dose of Dryvax vaccine virus [Wyeth Labs, Marietta,
PA] by scarification, January, 2002, current vaccinia neutralizing
antibody titer of 1:32). Serum was tested for standard neutralization
assay. Briefly, 0.1 mL of serial twofold dilutions of each serum was
mixed with an equal volume of vaccinia virus suspension contain-
ing ~100 TCID50. After incubation, virus-antibody mixtures, medi-
um, and virus controls were inoculated onto monolayers of Vero
cells seeded in 96-well plates. Concomitant retitration of virus sus-
pension was run in parallel. After 48-h incubation at 37°C, the cyto-
pathic effect was observed under light microscope, and the
microplates were stained with crystal violet. For T-cell assays,
peripheral blood mononuclear cells cultures were stimulated with
vaccinia virus (panels A–C) or cytomegalovirus antigens (panels
D–F), and intracellular IFN-g synthesis was analyzed in CD3(+) T
cells. Percentages in panel quadrants refer to total lymphocytes.previously observed (14), vaccinia-specific T cells could be
detected by flow cytometry only a few days after immu-
nization with vaccinia virus. In addition, Pincus and Flick
demonstrated the initial development of delayed hypersen-
sitivity, an index of cell-mediated immunity, as early as 2
days after smallpox vaccination (15). During viral infec-
tion, high levels of virus-specific T cells are found in acute
infection, falling below detectable limits as the viral load
decreases and reappearing in chronic infections during
episodes of transient viremia. Accordingly, we observed
that the frequencies of HIV-specific CD8(+) T cells releas-
ing IFN-γ were quantitatively increased a few weeks after
viral rebound consequent to the interruption of antiviral
therapy (5). These observations indicate that the frequency
of virus-specific T cells is clinically relevant, which sug-
gests that this method may be useful in detecting immune
response by monitoring the frequency of virus-specific T
cells. In recently vaccinated persons, memory cells are
expanded by antigen reexposure, and their increase in fre-
quency could be quantitatively detected by the rapid flow
cytometric T-cell assay, confirming the efficacy of vaccina-
tion. Moreover, because of the high similarity between
orthopoxviruses, this rapid assay using vaccinia antigens
could be used to identify recently exposed persons.
Finally, an important aspect in developing a diagnostic
assay is to use a rapid and easily automated system that
works on virtually all persons who carry the disease. In
this context, the intracellular T-cell cytokine staining by
flow cytometry presents several advantages in comparison
to other techniques, such as tetramer staining and ELISpot
(4). In fact, flow cytometry allows for testing multiple pro-
teins or peptides at a single time and provides at the same
time a quantitative and phenotypic assessment of CD8(+)
and CD4(+) responding T cells. Moreover, optimization of
antigen preparation with peptide pools designed to be
virus-specific, highly conserved, and independent of HLA
haplotypes may allow for the development of a second
generation of more sensitive flow cytometric T-cell assays,
extending the possibility to perform routine analysis on
cryopreserved samples (4). The technique could be easily
automated through the use of analytical instruments
already available in most clinical laboratories that use flow
cytometry. In comparison with other analytical systems for
assessing antigen-specific responses, this method is eco-
nomically advantageous. The recent availability of mobile
flow-cytometer units may allow use of this assay under
field investigation conditions.
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